title: Current and future directions for Phase II trials in high-grade glioma.
abstract: Despite surgery, radiation and chemotherapy, the prognosis for high-grade glioma (HGG) is poor. Our understanding of the molecular pathways involved in gliomagenesis and progression has increased in recent years, leading to the development of novel agents that specifically target these pathways. Results from most single-agent trials have been modest at best, however. Despite the initial success of antiangiogenesis agents in HGG, the clinical benefit is short-lived and most patients eventually progress. Several novel agents, multi-targeted agents and combination therapies are now in clinical trials for HGG and several more strategies are being pursued.
authors.affiliation: Department of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, 75 Francis Street, ASB1-L2, Boston, MA 02115, USA.
authors.forename: Brian M
authors.initials: BM
authors.lastname: Alexander
authors.forename: Eudocia Q
authors.initials: EQ
authors.lastname: Lee
authors.forename: David A
authors.initials: DA
authors.lastname: Reardon
authors.forename: Patrick Y
authors.initials: PY
authors.lastname: Wen
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy*; D017322:Clinical Trials, Phase II as Topic; D005910:Glioma / Q000188:drug therapy*; D006801:Humans; D060787:Neoplasm Grading
chemical_list: D000970:Antineoplastic Agents